ANG Lifesciences India Ltd Fair Value
ANGLIFESCIENCESINDIALTD · Healthcare · Current price
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹25 | -19% ROE fading to 14% over ~3 yrs, on ₹41 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is ANG Lifesciences India Ltd undervalued?
We couldn't compute a reliable fair value for ANG Lifesciences India Ltd from the available data. This usually means key inputs (earnings, book value, or cash flow) are missing or inconsistent.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹25). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹21 (bear) to ₹25 (base) to ₹29 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ANG Lifesciences India Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.